Unibio USA ApS: Financial statements 2022
CVR: 38179845
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Unibio USA ApS (CVR 38179845) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -18,000 and a net result of DKK -34,000 compared with DKK -12,000 the year before. Equity in the 2022 report amounted to DKK 88,000. The solvency ratio was 87.1%.
- Gross Profit
- DKK -18,000
- Profit/Loss
- DKK -34,000
- Equity
- DKK 88,000
- Total Assets
- DKK 101,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -18K | -34K | 88K | 0 |
| 2021 | - | -15K | -12K | 72K | 0 |
| 2020 | - | -14K | -11K | 8K | 0 |
| 2019 | - | -15K | -12K | 19K | 0 |
| 2018 | - | -15K | -12K | 31K | 0 |
Official annual report
Keep an eye on Unibio USA ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Unibio USA ApS has published its annual report for 2021. Gross profit came to DKK -15,000, and the net result was DKK -12,000.
About Unibio USA ApS
Unibio USA ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of David Richard Henstrom and Søren Olrik Eklund. The company is owned by UNIBIO A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a net result of DKK -20,000 compared with DKK -26,000 the year before. Equity in the 2025 report amounted to DKK 25,000.